Navigation Links
Hagens Berman Appointed Co-Lead Counsel in Case Against Schering-Plough and Merck

Lawsuit claims manufacturers misled consumers about the use of Zetia and


SEATTLE, June 10 /PRNewswire/ -- Last week the U.S. District Court in New Jersey appointed Hagens Berman, along with four other firms, co-counsel in a case against Schering-Plough (NYSE: SGP) and Merck (NYSE: MRK) which claims the companies knowingly misled consumers on the use of popular prescription drugs Zetia and Vytorin.


Judge Dennis Cavanaugh approved and ordered an organizational structure consisting of five law firms to comprise a Plaintiffs Steering Committee which is responsible for coordinating plaintiffs during pretrial proceedings and more.

The order states that within one week defendants and plaintiffs are to submit a proposed schedule regarding the filing of a consolidated amended complaint.

The lawsuit, filed on Jan. 17, 2008, claims Schering-Plough and Merck violated state consumer protection laws arising from the sale and marketing of Zetia and Vytorin.

Zetia is a brand-name prescription drug used to lower LDL levels by decreasing cholesterol absorption in the intestinal tract. Vytorin is a combination of Zetia and Zocor, a statin available in generic form.

The suit claims that the combination of drugs was no more effective than the generic version of Zocor in blocking the fatty arterial plaques that can cause heart attack and stroke, as the manufacturers led consumers to believe since 2006.

The companies promoted Zetia heavily, claiming that by adding it to statin treatment, patients could more effectively lower LDL cholesterol which would, in turn, reduce plaque in patients' arteries, according to their advertisements.

But according to the complaint, the companies had prior information that refuted that claim.

To view updates on the case and additional court documents please visit You can contact plaintiff's attorneys, Steve Berman or Craig Spiegel at (206) 623-7292 or via e-mail at

About Hagens Berman

Hagens Berman, formally Hagens Berman Sobol Shapiro, is based in Seattle with offices in Chicago, Cambridge, Los Angeles, Phoenix and San Francisco. Since 1993, it has developed a nationally recognized practice in class-action and complex litigation. Among recent successes, HBSS has negotiated a $300 million settlement in the DRAM memory antitrust litigation; a $340 million recovery on behalf of Enron employees; a $150 million settlement involving charges of illegally inflated charges for the drug Lupron, and served as co- counsel on the Visa/Mastercard litigation which resulted in a $3 billion settlement, the largest anti-trust settlement to date. HBSS served as counsel in a $850 million Washington Public Power Supply settlement and represented Washington and 12 other states against the tobacco industry that resulted in the largest settlement in history. For a complete listing of HBSS cases, visit


Steve Berman (206) 623-7292

Hagens Berman

Mark Firmani (206) 443-9357

Firmani + Associates Inc.

SOURCE Hagens Berman
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Gunther von Hagens BODY WORLDS Exhibitions Welcome Specimens From Worlds First Living Body Donor for Plastination
2. Gunther Von Hagens BODY WORLDS Exhibitions Mark 25th Million Visitor Milestone
3. Hagens Berman Sobol Shapiro: Nationwide Class Action Certified in Average Wholesale Price Litigation
4. Hagens Berman: Eleven Defendants Settle in Average Wholesale Price Litigation
5. Anatomist Dr. Gunther von Hagens Clarifies: Plastinates Not For Sale
6. CORRECTED: Hagens Berman Sobol Shapiro Files Suit Against Merck and Schering-Plough
7. Hagens Berman Sobol Shapiro Announces Investigation Into Marketing of Vytorin and Zetia
8. Hagens Berman Sobol Shapiro: Judge Orders Double Damages, Issues Stinging Rebuke in Average Wholesale Price Case
9. Rulings Send Lawsuits Against State Farm, American Family Back to Court, Hagens Berman Sobol Shapiro Announces
10. Jeff Bailet, M.D., Appointed to American Medical Associations Advisory Committee
11. David Pizzo Appointed Blue Cross and Blue Shield of Florida Market President - West Florida
Post Your Comments:
(Date:11/25/2015)... CA (PRWEB) , ... November 25, 2015 , ... According ... Vinci surgical robot is being more and more widely heralded as a breakthrough for ... da Vinci method has over traditional laparoscopic surgery is that it can greatly reduce ...
(Date:11/25/2015)... ... November 25, 2015 , ... The McHenry County law firm ... appellate decision obtained by Attorneys Francisco J. Botto and Alex C. Wimmer. Attorneys Botto ... Compensation Comm’n, 2015 IL App (2d) 130884WC. , According to court documents, Adcock testified ...
(Date:11/25/2015)... ... November 25, 2015 , ... Brillianteen, McGaw ... and learning in its 65th Anniversary Brillianteen Revue, scheduled for March 4-6, 2016. ... For 65 years, Brillianteen has been a treasured tradition for numerous families in ...
(Date:11/25/2015)... ... November 25, 2015 , ... In ... nation’s Periwinkle Pioneers, individuals and groups responsible for advancing care for pulmonary hypertension ... Pioneers, nominated by the public, will receive special recognition throughout 2016 as part ...
(Date:11/25/2015)... ... November 25, 2015 , ... Bcureful—a non-profit organization devoted ... as raising public awareness of the disorder while helping to bring expert medical ... $35,000 to bolster progress at the Tuberous Sclerosis Complex Center at Ann & ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... , Nov. 25, 2015  Amgen (NASDAQ: AMGN ... Application (BLA) with the United States ... 501, a biosimilar candidate to Humira ® (adalimumab). ... application submitted to the FDA and represents Amgen,s first ... Sean E. Harper , M.D., executive vice president of ...
(Date:11/25/2015)... 2015 On Tuesday, November 24, 2015, ... against Wright Medical Technology, Inc. for product liability ... hip implant device, awarded $11 million in favor ... trial and three days of deliberations, the jury ... defectively designed and unreasonably dangerous, and that Wright ...
(Date:11/25/2015)... Allergan plc (NYSE: AGN ) today announced that it ... State Attorney General,s Office to end the litigation ... with the Attorney General over the decision of Forest Laboratories, ... the now generic version of memantine immediate release tablets.  Under ... its counterclaims against New York , and ...
Breaking Medicine Technology: